Value-based agreements (VBAs) between payers (insurers/healthcare provider) and manufacturers (pharma/drug developers) are an innovative method to reduce price-value misalignment for novel therapies. Lyfegen offers a platform for automated execution of VBAs, prediction of the agreement’s value and a proprietary library of VBA models. These agreements align the price paid by payers to manufacturers as a function of the therapy effectiveness. This allows more patients access to innovative and expensive treatments like gene-, cell- and immuno- therapies. Simultaneously, drug manufacturers gain access to more patients for clinical evidence collection.
Girisha Fernando, Nico Mros, Frederico Braga, Michel Mohler
aMoon Fund, ARPIG
APEX Ventures GmbH